Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers

Ayat Lashen(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Mashael Algethami(University of Nottingham), Shatha Alqahtani(University of Nottingham), Ahmed Shoqafi(University of Nottingham), Jennie N. Jeyapalan(University of Nottingham), Nigel P. Mongan(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust)

International Journal of Molecular Sciences

May 6, 2024

10.3390/ijms25095053

Cited by 13

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

|The Lancet Oncology|2015|282